Phase 2
Completed N=25
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Source: ClinicalTrials.gov NCT00617994 ↗Enrolled (actual)
25
Serious AEs
4.0%
Results posted
Feb 2022
Primary outcomePrimary: Number of Treatment of Emergent Adverse Events — 2; 4; 2; 1 Participants
Summary
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Treatment of Emergent Adverse Events |
2; 4; 2; 1; 2 | — |
| PRIMARY Pharmacokinetics Parameter : Skin Flux of INCB018424 |
180; 131; 60; 151; 152 | — |
| PRIMARY Pharmacokinetics Parameter: Bioavailability of INCB018424 |
3.8; 4.1; 3.4; 3.9; 5.2 | — |
| PRIMARY Pharmacokinetics Parameter: Plasma Concentrated Steady State (CSS) of INCB018424 |
7.00; 28.38; 24.41; 34.97; 60.98 | — |
| SECONDARY Psioriatic Lesion Severity: Change in Total Lesion Score for the Target Lesion Compared to Baseline |
.4; -1.4; -0.8; -4.0; -0.2; -1.2 | — |
| SECONDARY Mean Change in Psoriatic Lesion Area |
-2.20; -237.76; -15.94; -620.56; 0.40; -1267.78 | — |
| SECONDARY Mean Change in Physicians Global Assessment Score |
4.4; 4.4; 4.2; 4.4; 4.0; 4.0 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must have psoriatic lesions measuring protocol specific BSA
Exclusion Criteria
- Lesions solely involving the palms of the hands, the soles of the feet, the intertriginious areas, the scalp or the face
- Pustular psoriasis or erythroderma
Data sourced from ClinicalTrials.gov (NCT00617994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.